{"filings":[{"id":1387958,"accession_number":"0001034842-26-000045","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2026-07-01T20:11:51+00:00","items":["5.02"],"status":"ready","headline":"Rigel Pharmaceuticals appoints Alison Hannah as EVP, CMO; Lisa Rojkjaer departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alison L. Hannah, M.D. appointed Executive Vice President and Chief Medical Officer effective July 1, 2026.","Dr. Hannah resigned from the Board of Directors effective July 1, 2026; she had served as a board member since May 2021.","Lisa Rojkjaer, M.D. ceased as EVP and CMO and separated from the company effective June 25, 2026.","Dr. Hannah previously served as CMO of CytomX Therapeutics and as a consultant to the pharmaceutical and biotechnology industry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1111044,"accession_number":"0001034842-26-000043","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2026-06-17T20:05:28+00:00","items":["2.01"],"status":"ready","headline":"Rigel closes VEPPANU license with Arvinas/Pfizer; pays $70M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Rigel gains exclusive global rights to develop, manufacture and commercialize VEPPANU (vepdegestrant).","One-time upfront payment of $70 million made to Arvinas Inc., Arvinas Operations, Arvinas Estrogen Receptor, and Pfizer.","License agreement previously disclosed on May 12, 2026; HSR waiting period terminated early.","No additional upfront or milestone payment details provided beyond the $70 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554477,"accession_number":"0001034842-26-000041","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2026-05-20T20:10:19+00:00","items":["5.02","5.07"],"status":"ready","headline":"Rigel shareholders approve equity plan amendments adding 860K shares; re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2018 Equity Incentive Plan, adding 500,000 shares.","Stockholders approved amendment to 2000 ESPP, adding 360,000 shares.","Directors Alison Hannah, Walter Moos, Raul Rodriguez re-elected with >86% votes cast in favor.","Advisory say-on-pay approved with 9,013,480 votes for (87.5% of votes cast).","Ratification of Ernst & Young as FY2026 auditor passed with 12,590,773 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":42883,"accession_number":"0001034842-26-000038","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2026-05-12T21:24:38+00:00","items":["1.01"],"status":"ready","headline":"Rigel licenses VEPPANU (vepdegestrant) from Arvinas/Pfizer; $70M upfront plus milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $70M, plus $15M on transition completion; total potential milestones up to $320M.","Tiered royalties on net sales from mid-teens to mid-twenties percent; sublicense revenue sharing.","Rigel gets exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU.","VEPPANU approved in US for ER+/HER2- ESR1-mutated advanced/metastatic breast cancer.","Deal subject to HSR waiting period expiration or termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90730,"accession_number":"0001034842-26-000033","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q1 revenue up 26% to $58.8M, net income $8.7M; reaffirms FY2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 total revenues $58.8M (net product sales $54.9M, contract $3.9M), up 26% YoY.","Net income $8.7M ($0.44 diluted EPS) vs. $11.4M ($0.63 diluted) in Q1 2025.","TAVALISSE sales $37.3M (+31%), GAVRETO $9.6M (+7%), REZLIDHIA $8.0M (+31%).","Eli Lilly to terminate ocadusertib collaboration effective June 15, 2026.","Restructured $40M MidCap revolver; repaid $40M term loan, drew $8M on new facility."],"consensus_eps_estimate":0.697,"consensus_eps_actual":0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":58818000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90729,"accession_number":"0001034842-26-000027","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Lilly terminates ocadusertib license deal with Rigel; effective June 15, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lilly elected to terminate the License and Collaboration Agreement for ocadusertib on April 16, 2026; effective June 15, 2026.","Rigel will regain full rights to ocadusertib and associated RIPK1 inhibitors after termination.","CNS disease program under the agreement was already terminated effective November 2025.","Rigel does not expect to receive any future milestones or royalties under the terminated agreement.","Rigel is evaluating the impact; no financial guidance or changes provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100493,"accession_number":"0001034842-26-000016","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q4 net product sales $65.4M record; full year net income $367M, includes $245.9M tax benefit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net product sales $65.4M (+41% YoY); TAVALISSE $45.6M (+47%), GAVRETO $10.2M (+27%), REZLIDHIA $9.6M (+29%).","Full year 2025 net product sales $232M (+60% YoY); total revenue $294.3M.","Q4 net income $268.1M ($14.72 basic EPS) includes $245.9M non-cash deferred tax benefit; FY net income $367M.","2026 guidance: total revenue $275-290M, net product sales $255-265M, expects positive net income.","Cash $155.0M at Dec 31, 2025 vs $77.3M at Dec 31, 2024; R289 dose expansion enrollment on track for H2 2026 RP2D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100492,"accession_number":"0001034842-26-000007","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rigel appoints Michael P. Miller to board, effective Feb 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael P. Miller appointed to Rigel board effective Feb 1, 2026; term expires at 2027 annual meeting.","Miller will serve on Compensation Committee; receives $50k annual retainer plus $10k for committee.","Initial option grant of 12,000 shares under 2018 Plan; annual grants of 3,000 options + 2,500 RSUs thereafter.","Board determined Miller is independent under applicable standards; no family relationships or transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100491,"accession_number":"0001034842-26-000005","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Rigel Pharmaceuticals Provides Preliminary Q4 2025 Revenue of $69.8M and 2026 Outlook of $275-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 total revenue $69.8M, net product sales $65.4M, vs $57.6M and $46.5M in Q4 2024.","Full year 2025 total revenue $294.3M, net product sales $232.0M, up 60% from 2024.","2026 outlook: total revenue $275-290M, net product sales $255-265M, positive net income expected.","R289 Phase 1b study: RBC-TI achieved by 33% (6/18) evaluable patients at doses ≥500 mg QD; enrollment on track for RP2D selection H2 2026.","FDA approved boxed warning for GAVRETO (pralsetinib) for serious infections; postmarketing commitment met."],"consensus_eps_estimate":1.2717,"consensus_eps_actual":19.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":294282000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116815,"accession_number":"0001104659-25-119976","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rigel reports R289 Phase 1b data: 33% RBC-TI in evaluable lower-risk MDS patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["33 patients enrolled (median age 75, median 3 prior therapies); 61% high transfusion burden at baseline.","6/18 evaluable transfusion-dependent patients at doses ≥500 mg QD achieved RBC-TI >8 weeks; median duration 22.9 weeks.","R289 generally well tolerated; most common Grade 3/4 AEs: anemia (18%), neutropenia and pneumonia (each 15%).","Dose expansion phase ongoing; RP2D selection expected H2 2026.","R289 granted FDA Orphan Drug and Fast Track designations for MDS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116814,"accession_number":"0001104659-25-106282","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q3 net income $27.9M, raises 2025 revenue guidance to $285-290M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net income $27.9M ($1.46 diluted EPS) vs $12.4M ($0.70) in Q3 2024.","Total revenue $69.5M, record net product sales $64.1M (+65% YoY).","Raises 2025 total revenue guidance to ~$285-290M (prior $270-280M); product sales $225-230M.","TAVALISSE sales $44.7M (+70%), GAVRETO $11.1M (+56%), REZLIDHIA $8.3M (+50%).","R289 Ph1b dose expansion underway; Lilly terminates CNS collaboration (60-day effect)."],"consensus_eps_estimate":0.8718,"consensus_eps_actual":5.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":224480000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133262,"accession_number":"0001104659-25-074163","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q2 net income $59.6M, revenue $101.7M; raises FY2025 guidance to $270-280M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 total revenue $101.7M (net product sales $58.9M, up 76% YoY); net income $59.6M vs loss $1.0M in Q2 2024.","Raised FY2025 guidance: total revenue $270-280M (prev $200-210M); net product sales $210-220M (prev $185-192M).","Cash and investments increased to $108.4M from $77.3M at Dec 31, 2024.","TAVALISSE sales $40.1M (+52% YoY), GAVRETO $11.8M, REZLIDHIA $7.0M (+36%).","Completed enrollment in dose escalation part of Phase 1b study for R289 in R/R lower-risk MDS; dose expansion later this year."],"consensus_eps_estimate":2.6316,"consensus_eps_actual":3.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":155018000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149900,"accession_number":"0001104659-25-052407","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Rigel stockholders approve 700,000-share increase to equity plan, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2018 Equity Incentive Plan adding 700,000 shares.","Directors Kamil Ali-Jackson and Jane Wasman re-elected with 97.9% and 96.4% of votes cast, respectively.","Say-on-pay advisory resolution passed with 89.9% of votes cast.","Ratification of Ernst & Young as independent auditor approved with 93.1% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149899,"accession_number":"0001104659-25-045067","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q1 net income $11.4M vs loss; revenue $53.3M (+68% YoY); 2025 outlook reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $43.6M up 68% YoY: TAVALISSE $28.5M (+35%), GAVRETO $9.0M, REZLIDHIA $6.1M (+25%).","R289 granted FDA Orphan Drug (MDS) and Fast Track (lower-risk MDS); Phase 1b enrolling sixth dose level.","Patent settlement with Annora allows generic TAVALISSE license in Q2 2032 or earlier; litigation terminated.","Will not opt-in for ocadusertib; expects $40M non-cash revenue in Q2 from release of cost-share liability.","2025 outlook: total revenue $200-210M (excl. $40M one-time); positive net income expected for full year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":53333000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168918,"accession_number":"0001104659-25-028564","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rigel settles TAVALISSE patent litigation with Annora; generic entry in Q2 2032","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Entered settlement with Annora Pharma, Hetero Labs, and Hetero USA resolving patent litigation on TAVALISSE (fostamatinib).","Annora receives license to sell generic version in Q2 2032 or earlier under certain circumstances.","All ongoing litigation between Rigel and Annora in New Jersey terminated.","CEO Raul Rodriguez cites resolution as underscoring strength of TAVALISSE intellectual property."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168917,"accession_number":"0001104659-25-022224","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rigel Pharmaceuticals appoints Mark J. Frohlich to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed March 6, 2025; joins class of directors with term expiring at 2027 annual meeting.","Will serve on Corporate Governance, Health Care Compliance Oversight and Nominating Committee and Scientific and Clinical Trial Advisory Committee.","Received initial option grant for 12,000 shares; annual retainer $50,000 plus $10,000 per committee.","Board determined Frohlich is independent under SEC and Nasdaq standards; no familial relationships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168916,"accession_number":"0001104659-25-020313","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel reports 2024 net income $17.5M, record product sales $144.9M, guides FY25 rev $200-210M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["4Q total revenue $57.6M; TAVALISSE $31.0M (+21% YoY), REZLIDHIA $7.4M (+92% YoY), GAVRETO $8.1M.","FY24 total revenue $179.3M; net product sales $144.9M (+39% YoY); net income $17.5M vs loss $25.1M in FY23.","Cash & short-term investments $77.3M at year-end, up from $56.9M; expects positive net income in FY25.","FY25 guidance: total revenue $200-210M; net product sales $185-192M; contract revenues $15-18M.","R289 granted Fast Track and Orphan Drug designations for MDS; partner TAVALISSE approvals in South Korea and Mexico."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168915,"accession_number":"0001104659-25-002874","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Rigel reports prelim Q4 total revenue $57.6M, guides FY2025 rev $200-210M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q4 2024 total revenue $57.6M vs $35.8M Q4 2023; net product sales $46.5M.","TAVALISSE net sales $31.0M, REZLIDHIA $7.4M, GAVRETO $8.1M (launched June 2024).","Full-year 2024 total revenue $179.3M; cash & equivalents $77.3M at year-end.","2025 guidance: total revenue $200-210M; expects positive net income for the year.","R289 granted Orphan Drug designation by FDA for MDS; Phase 1b enrollment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186018,"accession_number":"0001104659-24-126758","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rigel reports initial Phase 1b data for R289 in LR-MDS; 40% response rate in evaluable TD patients at ≥500 mg QD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["22 LR-MDS patients enrolled; median age 76, median 3 prior therapies; 73% high transfusion burden.","R289 well tolerated; most common AEs diarrhea/fatigue (27%), chills/nausea/pruritus (23%), all Grade 1/2.","Among evaluable TD patients at doses ≥500 mg QD, 40% (4/10) achieved RBC-TI/HI-E; 3 achieved RBC-TI ≥8 weeks.","Two HTB patients achieved RBC-TI >24 weeks; median RBC-TI duration 29 weeks (range 12.7-51.9 weeks).","FDA granted Fast Track designation for R289 in previously-treated transfusion-dependent LR-MDS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186017,"accession_number":"0001104659-24-115334","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q3 net income $12.4M vs year-ago loss; revenue $55.3M, led by TAVALISSE +8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 revenue $55.3M; net income $12.4M ($0.71 basic EPS) vs net loss $5.7M in Q3 2023.","TAVALISSE net sales $26.3M (+8% YoY); REZLIDHIA $5.5M (+107% YoY); GAVRETO $7.1M (first full quarter).","Received $10M upfront from Kissei license for REZLIDHIA in Japan, Korea, Taiwan; up to $152.5M milestones.","R289 Phase 1b in LR-MDS: RBC-TI/hematologic improvement in 36% at doses ≥500 mg QD; median duration 29 weeks.","Cash and investments $61.1M at Sep 30, up from $49.1M at Jun 30 and $56.9M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":121682000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202597,"accession_number":"0001104659-24-101327","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Board member Dr. Brian Kotzin resigns from Rigel board effective Sept. 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Brian Kotzin resigned as independent director and from all committees, effective September 16, 2024.","Resignation not due to any disagreement with Rigel's operations, policies, or practices.","Kotzin chaired the Scientific and Clinical Trial Advisory Committee and served on the Corporate Governance, Healthcare Compliance, and Nominating committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202596,"accession_number":"0001104659-24-096047","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Rigel licenses olutasidenib to Kissei for Japan, Korea, Taiwan; $10M upfront + up to $152.5M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rigel receives $10M upfront; eligible for up to $152.5M in development, regulatory, and commercial milestones.","Mid-twenties to low-thirties percent tiered royalty on net sales; Kissei funds all development in territory.","Forma Therapeutics (Novo Nordisk) owed $2.3M from the upfront payment under prior sublicense.","Rigel retains global rights outside Japan, Korea, Taiwan; supplies bulk drug product under separate agreement.","Kissei responsible for companion diagnostic costs in Japan; Rigel shares 50% up to $3M, creditable against milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202595,"accession_number":"0001104659-24-086271","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q2 revenue $36.8M, net loss narrows to $1.0M; GAVRETO launch adds $1.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q2 revenue $36.8M; TAVALISSE $26.4M (+24% YoY), REZLIDHIA $5.2M (+102% YoY), GAVRETO $1.9M (launched June 27).","Net loss narrowed to $1.0M ($0.06/share) from $6.6M loss in Q2 2023; approaching net income break-even.","Completed NDA transfer of GAVRETO; product commercially available from Rigel beginning June 27.","Phase 1b trial of R289 in LR-MDS enrolling fourth dose level; preliminary data expected by end of 2024.","Cash and investments $49.1M as of June 30, essentially flat from March 31."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":66375000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218750,"accession_number":"0001104659-24-075697","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Rigel Pharmaceuticals effects 1-for-10 reverse stock split effective June 27, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-10 reverse split on June 15; effective June 27 at 12:01 a.m. ET.","Common stock now trades under new CUSIP 766559702.","No fractional shares issued; cash paid for fractions based on prior-day closing price.","Stockholders authorized a split ratio range of 1:2 to 1:20 at May 24, 2024 annual meeting.","Amendment to certificate of incorporation filed with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218749,"accession_number":"0001104659-24-074574","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rigel Pharmaceuticals announces 1-for-10 reverse stock split effective June 27, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10 ratio, reducing shares from ~175.6M to ~17.6M.","Effective June 27, 2024 at 12:01 a.m. ET; trading begins on split-adjusted basis same day.","Board approved final ratio on June 15, 2024, following stockholder approval on May 24, 2024.","Primary goal: raise per-share price to improve marketability and maintain Nasdaq $1 minimum bid compliance.","No fractional shares; cash in lieu paid. Authorized shares and par value unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218748,"accession_number":"0001104659-24-066058","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Rigel shareholders approve reverse stock split (1:2–1:20) and 6.5M share increase for equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of common stock at ratio between 1:2 and 1:20 approved; 87.85M for, 42.50M against.","Amended 2018 Equity Incentive Plan authorized additional 6.5M shares; 53.15M for, 48.24M against.","Two directors elected: Brian L. Kotzin (78.45M for) and Gregg A. Lapointe (79.15M for) to terms until 2027.","Advisory say-on-pay approved (74.74M for, 26.22M against); Ernst & Young ratified as auditor for FY2024.","Adjournment proposal passed (83.11M for) to allow further solicitation if needed for reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218747,"accession_number":"0001104659-24-058017","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q1 2024 revenue $29.5M, net loss $8.2M; acquires GAVRETO, appoints CMO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["TAVALISSE net sales $21.1M (down from $22.3M) but bottles shipped hit highest quarterly level since launch.","REZLIDHIA net sales $4.9M, up from $1.5M YoY, driven by increased demand.","Net loss improved to $8.2M ($0.05/sh) from $13.5M ($0.08/sh) in Q1 2023.","Acquired U.S. rights to GAVRETO (pralsetinib) for RET fusion-positive NSCLC/thyroid cancer; transition expected July 2024.","Cash and short-term investments $49.6M at March 31, 2024; credit facility amendment extended maturity by one year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":29534000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218746,"accession_number":"0001104659-24-046527","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Rigel amends MidCap credit agreement; maturity extended to Sep 2027, SOFR+6.50%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity date for term loans extended to September 1, 2027; interest-only period through October 1, 2025.","Interest rate set to SOFR plus 6.50% with a 4.00% floor; prepayment premium 1.5% through Sep 2025, then 1.0%.","Must maintain Borrower Unrestricted Cash of at least $10.0 million; TAVALISSE Net Revenue covenant triggered below 1.25x coverage.","Exit fee increased; amortization payments begin October 1, 2025; all principal due at maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238652,"accession_number":"0001104659-24-031010","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q4 net income $0.7M; TAVALISSE sales $25.7M (+17% YoY); acquires GAVRETO rights","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $35.8M, TAVALISSE net sales $25.7M (+17% YoY), REZLIDHIA net sales $3.9M (+333% YoY).","FY 2023 net loss $25.1M ($0.14/sh) vs $58.6M in 2022; revenue $116.9M, TAVALISSE $93.7M (+24% YoY).","Acquired U.S. rights to GAVRETO (pralsetinib) for RET+ NSCLC/thyroid cancer; expects sales recognition in Q3 2024.","Q4 TAVALISSE bottles shipped to patients/clinics: 2,463; REZLIDHIA bottles: 278 direct, QoQ growth 47%.","Cash & short-term investments $56.9M at Dec 31, 2023, vs $58.2M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238651,"accession_number":"0001104659-24-026338","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["1.01","2.01"],"status":"ready","headline":"Rigel acquires U.S. rights to Blueprint's pralsetinib for $15M plus milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $15M: $10M at first commercial sale, $5M one year after closing.","Up to $97.5M in commercial milestones and $5M in regulatory milestones.","Blueprint receives tiered royalties of 10-30% on net sales of pralsetinib products.","Pralsetinib is an approved RET inhibitor for metastatic NSCLC and advanced thyroid cancer.","Rigel expects to recognize product sales starting in Q3 2024 using its commercial infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238650,"accession_number":"0001104659-24-002085","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Rigel prelim Q4 2023 total revenue ~$35.7M; TAVALISSE record $25.7M; MD Anderson deal $15M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prelim Q4 total revenue ~$35.7M: TAVALISSE net sales $25.7M (record), REZLIDHIA $3.9M.","Full-year 2023 net product sales $104.3M (+36% YoY); cash & investments $56.9M at year-end.","Strategic collaboration with MD Anderson to advance REZLIDHIA in AML and other cancers; $15M in milestones over 5 years.","Collaboration with CONNECT for Phase 2 trial of REZLIDHIA in IDH1-mutant glioma; Rigel funding up to $3M.","Phase 1b trial of R289 (IRAK1/4 inhibitor) in lower-risk MDS currently enrolling third cohort."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256148,"accession_number":"0001104659-23-122171","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2023-11-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Rigel Pharma gets Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq deficiency letter on Nov 27, 2023 for bid price below $1.00 for 30 consecutive business days.","Has 180 calendar days, until May 28, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant by May 28, may be eligible for additional 180-day period if transfers to Nasdaq Capital Market.","Company may consider a reverse stock split to cure deficiency; no immediate effect on listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256147,"accession_number":"0001104659-23-115245","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q3 2023: Total revenue $28.1M, net loss narrows to $5.7M; TAVALISSE sales record $24.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $5.7M ($0.03/share) vs $19.0M ($0.11/share) in Q3 2022.","Total revenue $28.1M: TAVALISSE $24.5M (+27% YoY), REZLIDHIA $2.7M, collaboration $1.0M.","Cash and short-term investments $62.4M at Sep 30, 2023 vs $58.2M at Dec 31, 2022.","Phase 1b R289 (IRAK1/4 inhibitor) in LR-MDS enrolling third cohort; preliminary data expected mid-2024.","NECTAR trial fostamatinib arm ceased enrollment per DSMB recommendation; no safety concerns identified."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":81090000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273542,"accession_number":"0001104659-23-086368","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q2 net loss narrows to $6.6M; TAVALISSE sales up 15% YoY to $21.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $6.6M ($0.04/sh) vs $13.5M loss in Q2 2022; total revenue $26.9M.","TAVALISSE net product sales $21.3M (+15% YoY); REZLIDHIA sales $2.6M with 77% sequential bottle growth.","Cash, equivalents & investments $64.4M at June 30, up from $58.2M at Dec 31, 2022.","R289 Phase 1b in LR-MDS completed cohort 2 enrollment; R552 Phase 2a in RA initiated by Eli Lilly."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":52956000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290528,"accession_number":"0001104659-23-065988","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Rigel shareholders approve equity plan amendment adding 4M shares, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2018 Equity Incentive Plan, increasing authorized shares by 4,000,000.","Three directors elected: Alison L. Hannah, Walter H. Moos, Raul R. Rodriguez.","Advisory say-on-pay approved with 76.6 million votes for.","Board determined to hold annual advisory vote on executive compensation.","Ratification of Ernst & Young as independent auditor for fiscal 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290527,"accession_number":"0001104659-23-055028","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2023-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Pharma Q1 net loss narrows to $13.5M; TAVALISSE sales up 38% to $22.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.5M ($0.08/sh) improved from $27.4M ($0.16) in Q1 2022.","Total revenue $26.1M: TAVALISSE $22.3M (+38% YoY), REZLIDHIA $1.5M (first full quarter).","Shipped 2,256 TAVALISSE bottles to patients (highest quarter); 109 REZLIDHIA bottles shipped.","Accessed $20M term loan from MidCap; cash and investments $58.7M as of March 31.","Partner Kissei launched TAVALISSE in Japan; Lilly to begin Phase 2a trial of R552 in RA in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":26070000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311426,"accession_number":"0001104659-23-029558","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel reports Q4 2022 net income $1.4M on record TAVALISSE sales of $21.9M; full year revenue $120.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $51.3M ($21.9M TAVALISSE + $0.9M REZLIDHIA); net income $1.4M ($0.01/share) vs net loss $22.6M in Q4'21.","Full year 2022 net loss $58.6M ($0.34/share) on revenue $120.2M, compared to net loss $17.9M in 2021.","TAVALISSE 2022 net product sales $75.8M, up 20% YoY; Q4 bottles shipped to patients/clinics a record.","REZLIDHIA launched in Dec '22, $0.9M in Q4 sales; added to NCCN Guidelines for AML in Jan '23.","Cash and investments $58.2M at Dec 31, 2022, down from $125.0M at Dec 31, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311425,"accession_number":"0001104659-23-010536","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Rigel Pharmaceuticals CMO Wolfgang Dummer resigns, effective March 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wolfgang Dummer, EVP and Chief Medical Officer, will resign effective March 31, 2023.","Company has initiated a search for a new CMO with substantial hematology-oncology experience.","Dummer will continue in his role through the separation date and receive severance under the Executive Severance Plan.","Resignation deemed a Non-COC Qualifying Termination; requires full release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311424,"accession_number":"0001104659-23-002074","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Rigel reports preliminary Q4 revenue ~$51.3M; launches REZLIDHIA for AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 total revenue ~$51.3M including TAVALISSE $21.9M (+24% YoY) and REZLIDHIA $0.9M (launched Dec 22).","Recognized $20M milestone from Kissei for Japan PMDA approval of TAVALISSE in chronic ITP; payment expected Q1 2023.","Cash, equivalents and short-term investments ~$58.2M as of Dec 31, 2022 (vs $125.0M a year earlier).","REZLIDHIA (olutasidenib) FDA approved for R/R AML with IDH1 mutation; commercial launch underway.","First patients dosed in Phase 1b trial of R289 (IRAK1/4 inhibitor) for lower-risk MDS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330007,"accession_number":"0001104659-22-123853","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Rigel's REZLIDHIA for mIDH1 relapsed/refractory AML","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved REZLIDHIA (olutasidenib) for adult patients with relapsed/refractory AML with IDH1 mutation.","Phase 2 trial showed 35% CR+CRh rate (51/147) with median duration of response 25.9 months.","Median time to CR or CRh was 1.9 months; 92% of responders achieved CR.","Rigel acquired exclusive worldwide license from Forma Therapeutics in August 2022.","Conference call and webcast today at 6:30 p.m. ET to discuss approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330006,"accession_number":"0001104659-22-122864","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Rigel Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Rigel on Nov 22, 2022 that its common stock bid price closed below $1.00 for 30 consecutive business days.","Rigel has 180 calendar days, until May 22, 2023, to regain compliance by closing at $1.00 or more for at least 10 consecutive business days.","If not compliant by May 22, Rigel may be eligible for an additional 180-day period if it meets other listing standards and intends to cure via reverse stock split.","Failure to regain compliance could lead to delisting; Rigel may appeal a delisting determination.","No immediate effect on Nasdaq listing; stock continues to trade under RIGL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330005,"accession_number":"0001104659-22-114413","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["1.01","2.02","5.03","9.01"],"status":"ready","headline":"Rigel Q3 2022 net loss $19.0M, TAVALISSE sales up 20%, workforce cut 16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $19.0M ($0.11/sh) vs $21.0M loss a year ago; total revenue $22.4M.","TAVALISSE net product sales $19.2M, up 20% YoY from $16.0M.","Reduced workforce by 16% (30 positions) in development and administration.","Olutasidenib NDA under FDA review with PDUFA date Feb 15, 2023; preparations for launch.","FOCUS COVID-19 Phase 3 trial missed primary endpoint (p=0.0603); no sNDA for wAIHA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":68964000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330004,"accession_number":"0001104659-22-113463","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rigel's fostamatinib misses primary endpoint in Phase 3 COVID-19 trial; p=0.0603","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FOCUS Phase 3 trial of fostamatinib in high-risk hospitalized COVID-19 patients did not meet primary endpoint for days on oxygen (p=0.0603).","Mean days on oxygen were 6.9 for fostamatinib vs 9.0 for placebo; mortality 4 vs 8 deaths (50% reduction, p=0.4521).","All prespecified secondary endpoints numerically favored fostamatinib, including ordinal scale change to Day 15 (-2.4 vs -1.9, p=0.0428).","Safety profile consistent with prior experience; no new safety issues; study supported by U.S. Department of Defense.","Company evaluating next steps in collaboration with partner, U.S. Department of Defense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330003,"accession_number":"0001104659-22-107725","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["2.05","5.02","8.01","9.01"],"status":"ready","headline":"Rigel drops wAIHA sNDA after FDA feedback; cuts 16% workforce, 30 jobs","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA guidance on FORWARD Phase 3 re-analysis leads Rigel to halt sNDA for fostamatinib in wAIHA.","Workforce reduction of 16% (30 positions) primarily in development and admin; completion by Jan 31, 2023.","One-time cash severance charge of ~$1.5M in Q4 2022; expects $7-8M annual savings from 2023.","General counsel Dolly Vance retires effective Oct 11, 2022; remains as employee through Nov 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347569,"accession_number":"0001104659-22-085188","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Rigel Q2 TAVALISSE net product sales $18.6M; licenses olutasidenib from Forma; draws $10M term loan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["TAVALISSE net product sales of $18.6M, up 9% YoY; total revenues $29.8M; net loss $13.5M ($0.08/share).","Exclusive license from Forma for olutasidenib (mIDH1 inhibitor) for R/R AML; $2M upfront, up to $233M milestones; PDUFA Feb 15, 2023.","Amended MidCap credit agreement: extended maturity to Sept 2026, interest-only to Oct 2024; drew $10M fourth tranche term loan.","Completed enrollment (280 patients) in Phase 3 COVID-19 trial of fostamatinib; top-line data expected Q4 2022.","Knight license for TAVALISSE in Latin America: $2M upfront, up to $20M milestones; Kissei NDA submitted in Japan for ITP."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":46554000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347568,"accession_number":"0001104659-22-082470","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rigel files patent lawsuit against Annora to block generic TAVALISSE","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed suit in U.S. District Court for New Jersey against Annora Pharma, Hetero Labs, and Hetero USA for patent infringement.","Lawsuit responds to Annora's ANDA seeking FDA approval for a generic version of TAVALISSE (fostamatinib).","Annora sent Paragraph IV Notice Letter in June 2022 alleging the five asserted patents are invalid or not infringed.","Asserted patents: 7,449,458, 8,263,122, 8,652,492, 8,771,648, and 8,951,504 listed in the FDA Orange Book.","Rigel seeks equitable relief to enjoin Annora from infringing the patents covering TAVALISSE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364058,"accession_number":"0001104659-22-073906","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-06-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rigel receives Paragraph IV notice from Annora for generic TAVALISSE; intends to defend patents","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Annora Pharma filed ANDA with FDA for generic fostamatinib tablets (100mg and 150mg base).","Notice letter includes Paragraph IV certifications alleging Rigel's TAVALISSE patents are invalid or not infringed.","Rigel states it will vigorously enforce its intellectual property rights related to TAVALISSE.","TAVALISSE is Rigel's sole approved product; generic entry would materially impact revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364057,"accession_number":"0001104659-22-069317","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rigel FORWARD Phase 3 trial of fostamatinib in wAIHA misses primary endpoint overall; positive regional signals seen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint of durable hemoglobin response not met: fostamatinib 35.6% vs placebo 26.7% (p=0.398).","Post-hoc analysis: U.S./Canada/Australia/Western Europe showed significant benefit (36.0% vs 10.7%, p=0.03); Eastern Europe did not (35% vs 52.9%, p=0.304).","Safety profile consistent with prior data; most common AEs: diarrhea (26.7%), hypertension (24.4%), fatigue (15.6%).","Rigel plans further data analysis and discussion with FDA regarding regional differences.","71 of 90 patients (79%) enrolled in open-label extension study; data to be reported later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364056,"accession_number":"0001104659-22-063899","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Rigel stockholders approve 2018 Equity Plan amendment adding 5M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended 2018 Equity Incentive Plan increases authorized shares by 5,000,000, effective immediately after stockholder approval on May 19, 2022.","Vote on amendment: 72,954,216 for, 47,859,509 against, 1,366,196 abstain, 19,065,889 broker non-votes.","Stockholders elected directors Kamil Ali-Jackson and Jane Wasman to terms expiring at 2025 annual meeting.","Say-on-pay advisory vote approved: 113,344,916 for, 7,265,856 against, 1,569,149 abstain.","Ernst & Young ratified as independent auditor for FY2022: 133,170,094 for, 7,845,051 against, 230,665 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364055,"accession_number":"0001104659-22-055272","cik":1034842,"company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rigel Q1 net loss $27.4M vs prior-year net income; TAVALISSE sales up 31%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.4M ($0.16/sh) vs net income of $39.5M ($0.23/sh) in Q1 2021.","Total revenues $16.7M: TAVALISSE net product sales $16.2M (+31% YoY); contract revenues $0.5M.","Cash and short-term investments $107.5M at March 31, down from $125.0M at Dec 31, 2021.","FORWARD Phase 3 wAIHA trial topline data expected mid-2022; potential first-to-market therapy if approved.","COVID-19 fostamatinib trial enrolled 268 of 308 patients; evaluating completion strategies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":16735000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":555617481.3470149,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-03T23:59:59+00:00|364055"}